Clinical trials: High-Risk Cancer, open to volunteers
Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia
Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS
This phase II trial studies the effect of venetoclax together with busulfan, cladribine, and fludarabine in treating patients with high-risk acute myeloid leukemia or myelodysplastic syndrome who are undergoing stem cell…
- Conditions
- Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT04708054
- Testing
- Busulfan, Cladribine, Fludarabine Phosphate
- Where
- United States
- Volunteers
- 324 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Gynecologic Cancer
High-frequency Ultrasound for Intraoperative Lymph Node Assessment in Gynecological Cancer: From Surgery to Radiomics
Lymph node assessment is crucial in gynecological cancers (ovarian, endometrial, cervical, and vulvar), as nodal involvement significantly impacts prognosis and treatment.
- Trial name
- RHINOCERUS (NCT06906705)
- Where
- Italy
- Volunteers
- 160 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Lung Cancer, Lung Carcinoma
Lung Cancer Screening in High-risk Black Individuals
The goal of this research study is to study U.S. Black individuals with a history of smoking to examine the feasibility, acceptability, and performance of low-dose computed tomography (LDCT) screening among this population.
- Trial name
- NCT05898594
- Testing
- Low-dose Computed Tomography
- Where
- 2 sites in United States
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Hepatocellular Carcinoma (HCC), Radiotherapy-Induced Immune Priming
PULSAR Radiotherapy Combined With Immunotherapy for High-Risk Advanced Liver Cancer
The goal of this clinical trial is to learn if adding PULSAR, a personalized adaptive stereotactic radiotherapy, to standard immunotherapy can control cancer longer in adults with high-risk advanced hepatocellular carcinoma…
- Conditions
- Hepatocellular Carcinoma (HCC), Radiotherapy-Induced Immune Priming, Immunotherapy
- Trial name
- HCC-PULSAR (NCT07884877)
- Testing
- PULSAR (Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy), Immune checkpoint inhibitor-based therapy
- Where
- South Korea
- Volunteers
- 38 people
- Sponsor
- Samsung Medical Center
Adenocarcinoma of the Pancreas, Adenocarcinoma of the Duodenum
Efficacy and Safety of TPIAT for Resectable Adenocarcinoma of the Pancreas Region at High Risk of Postoperative Fistula
Curative management of locally resectable invasive adenocarcinomas located in the cephalic region of the pancreas (pancreas, duodenum and ampulla of Vater) requires a pancreaticoduodenectomy followed by adjuvant chemotherapy.
- Conditions
- Adenocarcinoma of the Pancreas, Adenocarcinoma of the Duodenum, Ampullary Adenocarcinoma
- Trial name
- TPIAT-01 (NCT05116072)
- Testing
- total pancreatectomy, intraportal islet autotransplantation
- Where
- France
- Volunteers
- 36 people
- Sponsor
- University Hospital, Lille
Basal Cell Carcinoma
Neoadjuvant Nivolumab + Relatlimab (Opdualag) Versus Nivolumab for Resectable High-Risk Basal Cell Carcinoma
This is a Phase 2 clinical trial with a 2:1 randomization comparing neoadjuvant Nivolumab + Relatlimab (Opdualag) vs neoadjuvant Nivolumab in patients with resectable high risk basal cell carcinoma (HR BCC)
- Trial name
- NEON (NCT06624475)
- Testing
- Nivolumab, Relatlimab plus Nivolumab
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- University of California, San Diego
High Risk Smoldering Multiple Myeloma (HR-SMM)
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
This study is researching an experimental drug called linvoseltamab (also called "study drug") compared to another drug called daratumumab, in participants with Smoldering Multiple Myeloma (SMM), who are at a High Risk (HR) of…
- Trial name
- LINKER-SMM2 (NCT07393282)
- Testing
- Linvoseltamab, Daratumumab
- Where
- 27 sites in United States, Japan and 3 more
- Volunteers
- 270 people
- Sponsor
- Regeneron Pharmaceuticals
GC/GEJC
Disitamab Vedotin Combined With SOX Regimen Versus SOX Alone as Adjuvant Therapy for HER2-Moderate/High Expressing Stage Ⅲ Gastric Cancer: A Prospective, Multicenter, Randomized, Phase Ⅱ Clinical Trial
This is a prospective, multicenter, randomized, phase II clinical trial intended to enroll patients with HER2-moderate/high-expressing, pathologically staged stage III gastric cancer who have undergone D2 or more extensive…
- Trial name
- NCT07474324
- Testing
- RC48, SOX Chemotherapy, SOX(normal)
- Where
- China
- Volunteers
- 124 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Prostate Cancer
Improving Engagement From Underserved Communities With Prostate Cancer Genetics Services
Earlier work explored barriers and facilitators to accessing prostate cancer screening, particularly in underserved communities, and provided valuable insights to build upon.
- Trial name
- INCLUDE PC (NCT07407686)
- Testing
- Surveys, Semi-structured interviews and focus groups
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Royal Marsden NHS Foundation Trust
Breast Cancer, Cancer of Breast
Navigation Interventions for Patients With Breast Cancer and High-risk Social Determinants of Health
This study aims to assess how individual patient social stressors are associated with barriers to care by analyzing a patient navigator system.
- Trial name
- NCT07781800
- Testing
- Patient navigator
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- Washington University School of Medicine
Pediatric Osteosarcoma
Evaluating Efficacy of B7-H3-CAR T Cells Administered at the End of Upfront Map Chemotherapy in Patients With Newly Diagnosed High-Risk Osteosarcoma
The purpose of this study is to assess the safety, feasibility, and effectiveness of a consolidative B7-H3 CAR T cell therapy in patients with newly diagnosed high-risk osteosarcoma who have undergone upfront standard…
- Trial name
- NCT07428993
- Testing
- Cyclophosphamide, Fludarabine, Mesna
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- St. Jude Children's Research Hospital
Germline Mutations
Early Diagnosis of High-grade Serous Epithelial Ovarian Cancer Through the Analysis of DNA Derived From Pap Test Smear.
Ovarian cancer is the leading cause of death among gynecological malignancies. No screening test is available for this tumor. Serous Tubal Intraepithelial Carcinoma (STIC) is the precursor lesion of the high grade serous ovarian…
- Trial name
- EVATEST (NCT07556562)
- Testing
- RRSO (risk-reducing salpingo- oophorectomy) or RRS (risk-reducing salpingectomy)
- Where
- Italy
- Volunteers
- 260 people, healthy volunteers welcome
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
IB-II Gastric Cancer
A Clinical Study Comparing Anti-HER2 Therapy Combined With Chemotherapy to Chemotherapy Alone as Adjuvant Therapy Following Surgery for Stage IB-II Gastric Cancer With High HER2 Expression.
This study employs a multicenter randomized controlled trial design, led by the First Affiliated Hospital of Air Force Medical University (Xijing Hospital) in collaboration with 10 other domestic medical institutions, for a total…
- Trial name
- NCT07788196
- Testing
- Trastuzumab, Monotherapy with tegafur for stage IB gastric cancer, Stage II gastric cancer treated with the SOX or XELOX regimens
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Xijing Hospital
Acute Myeloid Leukemia, Consolidation Therapy
Venetoclax Combined With Azacitidine for Consolidation Therapy in AML
The goal of this clinical trial is to compare the efficacy and safety of a venetoclax-based consolidation therapy versus conventional consolidation chemotherapy in newly diagnosed adult patients with high-risk acute myeloid…
- Conditions
- Acute Myeloid Leukemia, Consolidation Therapy, Venentoclax, High Risk
- Trial name
- NCT07425782
- Testing
- Ara-C Group, VEN/AZA condsolidation
- Where
- China
- Volunteers
- 216 people
- Sponsor
- The First Affiliated Hospital of Soochow University
GBM, Glioblastoma Multiforme (GBM)
Focused Ultrasound Blood-Brain Barrier Disruption for the Treatment of High-Grade Glioma in Patients Undergoing Standard Chemotherapy
The goal of this clinical trial is to evaluate the safety and feasibility of focused ultrasound (FUS)-mediated blood-brain barrier (BBB) disruption using the Next Generation Dome Helmet (NGDH) in adults with glioblastoma (GBM)…
- Conditions
- GBM, Glioblastoma Multiforme (GBM), Glioblastoma Multiforme of Brain, Glioblastoma Multiforme Glioma
- Trial name
- NCT07179328
- Testing
- Focused Ultrasound Next Generation Dome Helmet, Definity® Vial for (Perflutren Lipid Microsphere) Injectable Suspension
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- Sunnybrook Health Sciences Centre
High-grade Serous Ovarian Cancer, Circulating Tumor DNA
CtDNA as a Novel Biomarker of Treatment Efficacy in Patients With Ovarian Cancer
This study is a prospective observational clinical trial. Patients who were diagnosed and treated for the first time were enrolled and their surgical pathology was confirmed to be high-grade serous ovarian cancer.
- Trial name
- NCT05027828
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Advanced Solid Tumors, Breast Cancer Recurrent
First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
The goal of this study is to identify a safe and tolerated dose of the orally administered KIF18A inhibitor ATX-295. In addition, this study will evaluate the pharmacokinetics, pharmacodynamics and preliminary antitumor activity…
- Conditions
- Advanced Solid Tumors, Breast Cancer Recurrent, Ovarian Cancer, High-grade Serous Ovarian Carcinoma
- Trial name
- NCT06799065
- Testing
- ATX-295, ATX-295 and bevacizumab (or biosimilar)
- Where
- 11 sites in United States
- Volunteers
- 218 people
- Sponsor
- Accent Therapeutics
Tubo-ovarian Carcinoma, High-grade Serous Carcinoma
Risk-reducing Strategies, Including Fimbriectomy, in Women With a Germline Mutation Predisposing to Ovarian or Pelvic Cancer
FIMBRIMENOP-2402 study aims to evaluate the long-term management of cancer risks in premenopausal women who have a genetic predisposition to tubo-ovarian or primary peritoneal carcinoma, such as mutations in BRCA1, BRCA2, RAD51C…
- Conditions
- Tubo-ovarian Carcinoma, High-grade Serous Carcinoma, Primary Peritoneal Carcinoma Stage III, Primary Peritoneal Carcinoma Stage IV
- Trial name
- FIMBRIMENOP (NCT06726330)
- Testing
- Fimbriectomy Followed by Delayed Oophorectomy (F-DO), Bilateral Salpingo-Oophorectomy
- Where
- 23 sites in France
- Volunteers
- 1,100 people
- Sponsor
- Centre Oscar Lambret
Thyroid Cancer
Adjuvant Radiotherapy in High Risk Locally Advanced DTC
This study is a phase III randomized controlled clinical trial on the role of adjuvant radiotherapy in high-risk locally advanced differentiated thyroid cancer.
- Trial name
- NCT06558981
- Testing
- Radiotherapy, radioiodine treatment
- Where
- China
- Volunteers
- 124 people
- Sponsor
- Fudan University
Lymphoma, Large B-Cell, Diffuse
A Phase III Clinical Trial of High-dose Rituximab (500mg/m²) Combined With CHOP Regimen in the Treatment of Male Patient With Newly Diagnosed Advanced DLBCL
Comparison of MODIFIED progression-free survival (Modified-PFS) in high-dose rituximab (500mg/m²) plus CHOP versus standard-dose rituximab plus CHOP in previously untreated (TN) stage III-IV male DLBCL patients
- Trial name
- NCT06573645
- Testing
- Rituximab
- Volunteers
- 428 people
- Sponsor
- Xia Yi
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.